Mehta Vimal 4
4 · BioXcel Therapeutics, Inc. · Filed Mar 16, 2026
Research Summary
AI-generated summary of this filing
BioXcel (BTAI) CEO Vimal Mehta Exercises RSUs
What Happened
Vimal Mehta, CEO, President and a director of BioXcel Therapeutics (BTAI), reported converting a total of 383 derivative awards into common shares via two exercises/conversions: 164 shares on March 14, 2026 and 219 shares on March 15, 2026. The filing shows $0 cash consideration for the conversions (reported as derivative exercises), indicating RSUs/derivatives were converted into shares rather than sold for cash.
Key Details
- Transaction dates: March 14, 2026 (164 shares) and March 15, 2026 (219 shares) — total 383 shares converted.
- Reported price/value: $0.00 reported on the disposition lines for the derivative conversion; acquisition price listed as N/A. No cash proceeds reported.
- Filing: Form 4 filed March 16, 2026 for transactions occurring March 14–15 (filed timely).
- Shares owned after transaction: not specified in the filing.
- Footnotes of note:
- F1: Each RSU represents a contingent right to receive one share of common stock.
- F2: Some securities are held of record by BioXcel LLC (a subsidiary of BioXcel Holdings); Mr. Mehta may be deemed to beneficially own those shares due to his roles, but he disclaims beneficial ownership except to the extent of any pecuniary interest.
- F3/F4: The reported RSUs stem from grants on Mar 14, 2022 (2,609 RSUs) and Mar 15, 2023 (3,500 RSUs) with multi-year vesting schedules — the conversions likely reflect vested portions of those grants.
Context
This filing documents conversion/exercise of restricted stock units (derivative awards) into common shares, not an open-market sale or purchase. Conversions like this typically reflect vesting and the issuance of shares rather than a buy/sell decision; they do not by themselves signal a bullish or bearish view.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-03-14+164→ 21,040 total - Exercise/Conversion
Common Stock
[F1]2026-03-15+219→ 21,259 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-03-14−164→ 488 total→ Common Stock (164 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F4]2026-03-15−219→ 1,532 total→ Common Stock (219 underlying)
- 125(indirect: By Spouse)
Common Stock
- 480,343(indirect: By LLC)
Common Stock
[F2]
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
- [F3]On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
- [F4]On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.